Serum Oxidative Stress-Induced Repression of Nrf2 and GSH Depletion: A Mechanism Potentially Involved in Endothelial Dysfunction of Young Smokers by Fratta Pasini, Anna et al.
Serum Oxidative Stress-Induced Repression of Nrf2 and
GSH Depletion: A Mechanism Potentially Involved in
Endothelial Dysfunction of Young Smokers
Anna Fratta Pasini*, Anna Albiero, Chiara Stranieri, Mattia Cominacini, Andrea Pasini, Chiara Mozzini,
Paola Vallerio, Luciano Cominacini, Ulisse Garbin
Department of Medicine, Section of Internal Medicine D, University of Verona, Verona, Italy
Abstract
Background: Although oxidative stress plays a major role in endothelial dysfunction (ED), the role of glutathione (GSH), of
nuclear erythroid-related factor 2 (Nrf2) and of related antioxidant genes (ARE) are yet unknown. In this study we combined
an in vivo with an in vitro model to assess whether cigarette smoking affects flow-mediated vasodilation (FMD), GSH
concentrations and the Nrf2/ARE pathway in human umbilical vein endothelial cells (HUVECs).
Methods and Results: 52 healthy subjects (26 non-smokers and 26 heavy smokers) were enrolled in this study. In smokers
we demonstrated increased oxidative stress, i.e., reduced concentrations of GSH and increased concentrations of oxidation
products of the phospholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (oxPAPC) in serum and in
peripheral blood mononuclear cells (PBMC), used as in vivo surrogates of endothelial cells. Moreover we showed
impairment of FMD in smokers and a positive correlation with the concentration of GSH in PBMC of all subjects. In HUVECs
exposed to smokers’ serum but not to non-smokers’ serum we found that oxidative stress increased, whereas nitric oxide
and GSH concentrations decreased; interestingly the expression of Nrf2, of heme oxygenase-1 (HO-1) and of glutamate-
cysteine ligase catalytic (GCLC) subunit, the rate-limiting step of synthesis of GSH, was decreased. To test the hypothesis
that the increased oxidative stress in smokers may have a causal role in the repression of Nrf2/ARE pathway, we exposed
HUVECs to increasing concentrations of oxPAPC and found that at the highest concentration (similar to that found in
smokers’ serum) the expression of Nrf2/ARE pathway was reduced. The knockdown of Nrf2 was associated to a significant
reduction of HO-1 and GCLC expression induced by oxPAPC in ECs.
Conclusions: In young smokers with ED a novel further consequence of increased oxidative stress is a repression of Nrf2/
ARE pathway leading to GSH depletion.
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Introduction
Increasing data support the hypothesis that oxidative stress
provides an important pathophysiological link between cigarette
smoking and atherosclerosis [1,2]. Both the gas and tar phases of
cigarette smoke (CS) deliver a high concentration of oxidizing
chemicals, including reactive oxygen species (ROS), nitric oxide
(NO), peroxynitrite and free radicals [2,3] that can get into the
bloodstream and cause macromolecular damage in the vascular
cells [4].
The phospholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-phos-
phorylcholine (PAPC) is a major component of cell membranes
and lipoproteins. Oxidation products of PAPC (oxPAPC) are
found in atherosclerotic lesions, in cells during inflammation, in
membranes of apoptotic cells, as well as in oxidized low density
lipoproteins [5]. OxPAPC triggers inflammatory responses in vitro
and in vivo via increased expression of inflammatory genes and the
activation of monocyte binding to endothelial cells [6]. Among the
different oxPAPC 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-gly-
cero-3-phosphocholine (PEIPC), 1-palmitoyl-2-(5-oxovaleroyl)-sn-
glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-2-glutar-
oyl-sn-glycero-3-phosphorylcholine (PGPC) have been previously
identified as the most bioactive components [7].
Cigarette smoking is also associated with a depletion of
circulating endogenous antioxidants [1,2]. The tripeptide gluta-
thione (GSH) plays a key role in maintaining intracellular
reduction–oxidation (redox) balance and in establishing the
mechanisms of cellular defences augmented by oxidative stress
[8,9]. The rate-limiting step of the de novo synthesis of GSH is
catalysed by glutamate-cysteine ligase, a heterodimer composed of
a catalytic heavy chain (GCLC) and a modifier (or regulatory) light
chain [9]. The transcription of human GCLC is mainly regulated
by nuclear erythroid-related factor 2 (Nrf2), a redox-sensitive
transcription factor that plays a major role in antioxidant response
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Under basal conditions, Nrf2-dependent transcription is repressed
by its negative regulator Keap1. When cells are exposed to
oxidative stress or electrophiles, Nrf2 accumulates in the nucleus
and drives the expression of its target genes [10]. Among the
spectrum of antioxidant genes controlled by Nrf2 heme-oxygen-
ase-1 (HO-1) [11] and GCLC are of particular interest, especially
in CS-induced oxidative stress [12].
Endothelial dysfunction is well established as one of the primary
events in the pathogenesis of atherosclerosis [13] and a predictor
of cardiovascular (CV) disease [14]. Previous studies have shown
that long-term cigarette smoking produces impairment of flow-
mediated dilation (FMD) [15–17]. Although decreased NO
bioavailability and increased generation of ROS play a critical
role in CS-related endothelial dysfunction [15,18–19] there is
recent evidence showing that GSH is important in the regulation
of endothelial dysfunction in smokers [20]. However the precise
mechanisms and, in particular, the role of the protective Nrf2/
ARE signalling pathway are not yet known. We have recently
demonstrated an increased formation of oxPAPC and a negative
regulation of Nrf2/ARE pathway in peripheral blood mononu-
clear cells (PBMC) of young healthy heavy smokers [21].
Therefore, the aim of this study was to combine an in vivo model
with an in vitro model to assess whether cigarette smoking affects
FMD, GSH concentrations and the Nrf2/ARE pathway in
endothelial cells. Accordingly, we first evaluated FMD together
with GSH and oxPAPC in serum and in PBMC of young smokers
compared to non-smokers. Then serum from the same individuals
and increasing concentrations of oxPAPC were used to assess the
effect of smoking on intracellular GSH, ROS and NO
concentration, and on the expression of Nrf2/ARE pathway in
endothelial cells.
Methods
Ethics statement
The study was approved by the Ethical Committee of
University of Verona and all participants provided written consent
prior to commencing the study. All clinical investigations were
conducted according to the principles expressed in the Declaration
of Helsinki.
Study Population
Fifty-two (26 males and 26 females) healthy subjects, 20–35
years of age (mean 28.265 years) were enrolled in the study. None
of the participants had a history of hypertension, hypercholester-
olemia or diabetes mellitus, drank more than five units of alcohol
per week, were following a weight-reducing diet or exercised more
than 3630 min aerobic exercise per week. Furthermore, none of
the participants took antioxidants, anti-inflammatory or cardio-
vascular medications during or for six months prior to commenc-
ing the study. Of the 52 subjects, 26 were active cigarette smokers
with a mean cigarette number of 22.763.7/day, a mean duration
of smoking of 12.662.2 years, a mean cumulative cigarette
consumption of 14.864.3 pack/years and were thus assigned to
the smoking group. A pack year is defined as twenty cigarettes
smoked every day for one year. Smokers were asked to refrain
from smoking for at least 8 hours. The remaining 26 subjects did
not have a history of cigarette smoking and were assigned to the
non-smoking group.
Evaluation of FMD
Endothelial function was assessed using a high-resolution B-
mode ultrasound (Envisor, Philips) equipped with a 7.5-to 12-MHz
linear array transducer to measure FMD of the brachial artery
(BA) in response to hyperaemia, which is currently the most
frequently used non-invasive surrogate of endothelial function
[22,23]. A B-mode scan of the right BA was obtained in
longitudinal section between 5 and 10 cm above the elbow; the
transducer was held at the same point throughout the scan by a
stereotactic clamp. After 1 min of acquisition to measure basal
diameter, a pneumatic cuff below the antecubital fossa (lower arm
occlusion) was inflated 50 mmHg above the systolic pressure for
5 min. Following deflation, the BA was imaged continuously for
3 min (endothelium-dependent dilation). A repeat baseline scan
was obtained after a 15-min rest. Endothelium-independent
dilation was obtained by the administration of sublingual glyceryl
trinitrate (GTN, 25 mg). We chose this small dose because it gives
an equivalent dilation to FMD, allows assessment of smooth
muscle function and reduces the concerns regarding potential side-
effects from large doses of GTN [23]. FMD and GTN-induced
dilation were defined as the maximal percent increment of the
diameter value with respect to the baseline, measured by a recently
developed system for real-time measurement of BA diameter
(FMD Studio, Institute of Clinical Physiology, CNR Pisa, Italy)
[24]. All exams were performed by the same operator blind to the
characteristics of the subjects. Each female subject was studied in
menstrual phase, since FMD in male subjects is comparable to that
in female subjects only in this phase [25].
Blood samples and PBMC isolation
Venous blood samples were obtained from each subject after
12 hours fasting and drawn into pyrogen-free blood collection
tubes. Multiple aliquots of serum were placed into sterile 1-ml
screw-capped polypropylene vials with phenolic antioxidant 2,6-
Di-tert-butyl-4-methylphenol 10 mmol/L (Sigma) added to inhibit
lipid peroxidation and stored at 280uC. The samples were frozen
and thawed only once. PBMC were isolated as previously
described [26]. Briefly, whole blood was layered onto a sterile
aqueous medium containing ficoll and sodium diatrizoate at a
predetermined density of 1.007 g/mL at 25uC. Gentle centrifu-
gation at room temperature resulted in the separation of PBMC at
the blood/ficoll interface, with the other white and red blood cells
passing through the interface. Total cholesterol, high density
lipoprotein (HDL) cholesterol, low density lipoprotein (LDL)
cholesterol, triglycerides and glucose were measured with standard
methods.
Evaluation of oxPAPC in serum and in PBMC from non-
smokers and smokers
OxPAPC in serum and in PBMC from non-smokers and
smokers were measured on an Agilent mass spectrometer
equipped with an electrospray source as previously described
[21,27]. The following different oxPAPC: PEIPC, POVPC and
PGPC were taken into consideration. Flow injection experiments
were performed by an HPLC system (HP1100; Agilent Technol-
ogies). Quantification of the peak areas was performed by single
ion monitoring in the elution time range of 10–20 min using
appropriate software. Authentic PAPC, POVPC (594.4 m/z) and
PGPC (610.2 m/z) were obtained from Avanti Polar Lipids, Inc.
(Alabaster, AL). PEIPC (828.5 m/z) was prepared and analyzed in
our laboratory as previously described [28].
Cell culture. Human umbilical vein endothelial cells
(HUVECs) from single donor were isolated, cultured as previously
described [29] and used at passages 2–4. Early apoptosis and cells
viabilityweredeterminedbyusingtheAnnexinV-FITCKit (Bender
MedSystem GmbH, Vienna, Austria) and 7-amino-actinomycin D
(7-AAD) (BD Biosciences) [30] by flow cytometry; cell proliferation
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previous observations [15,31], HUVECs were incubated without
and with increasing amounts (10, 30 and 50%) of serum derived
from non-smokers and smokers at different time points (0, 6 and
12 hours). Under these experimental conditions, no change of
Annexin V was observed compared with untreated cells (data not
shown) and no significant differences were observed in viability and
proliferation (data not shown) among HUVECs non treated or
treated with serum. This allowed us to conclude that any differences
were not attributable to a toxic effect on HUVECs. Endotoxin
contamination of cell cultures involving the use of serum was
routinely excluded with the chromogenic Limulus amoebocyte
lysate assay (Sigma). HUVECs were also incubated with the
corresponding amounts (10, 30 and 50%) of lipoprotein-depleted
serum (LPDS) derived from smokers, in which all the lipoproteins
weretaken away by ultracentrifugationat a density .1.21 g/mL, as
previously described [32].
In these experiments HUVECs were incubated with serum and
LPDS for 12 hours at 37uC because this time point allowed us to
evaluate GSH, ROS, NO and Nr2/ARE pathway expression
without affecting cell viability and proliferation.
Preparation of oxPAPC
PAPC was oxidized by air exposure for 48 hours and the
composition of oxPAPC was analyzed by ESI-MS Agilent as
previously described (28). 75 mg of oxPAPC yelded about 0.6–
0.7 mg/mL (1.01–1.17 mmol/L) of POVPC, about 0.38–0.45 mg/
mL (0.62–0.74 mmol/L of PGPC) and about 1.0–1.1 mg/mL
(1.20–1.32 mmol/L) of PEIPC. The lipids were extracted with
chloroform and resuspended in methanol before the addition to
the HUVECs. For the experiments HUVECs were incubated
without and with increasing concentrations (25–150 mg/mL) of
oxPAPC in M-199 containing 0.2% foetal calf serum (FCS) for
6 hours at 37uC. The concentration of oxPAPC (150 mg/mL)
contained concentrations of POVPC, PGPC and PEIPC similar to
those found in serum of smokers.
GSH measurement in serum, PBMC and in HUVECs
The detailed procedures for the measurement of cellular and
serum GSH have been previously described [33]. Samples were
directly collected into specially prepared tubes containing the
preservative 2,6-Di-tert-butyl-4-methylphenol (10 mmol/L) to
reduce auto-oxidation and frozen at 280uC. Samples were
analysed using high performance liquid chromatography with
fluorescence detection of 7-fluorobenzo-2-oxa-1,3-diazol-4-sulfon-
ic acid at excitation 385 nm and emission 515 nm.
Effect of increasing amounts of serum derived from non-
smokers and smokers, of LPDS derived from smokers and
of increasing concentrations of oxPAPC on ROS
measurement
Intracellular ROS levels were measured as described [29], by
following the oxidation of 29,79-dichlorofluorescin diacetate (DCFH-
DA) (Molecular Probes, Eugene, USA) by flow cytometry (Coulter
Corporation, Hialeah, Florida).Confluent HUVECs in 24-well tissue
culture plates were incubated without (control) and with increasing
amounts (10–50%) of serum (total volume 300 mL) derived from non-
smokers and smokers and with LPDS derived from smokers; the
supernatants were removed after 12 hours, cells washed and
10 mmol/L DCFH-DA was added to M-199 containing 10% FCS
for20 minat37uC. To evaluate the effect of oxPAPC on intracellular
ROS concentrations, some experiments were performed by adding
increasing concentrations (25–150 mg/mL) of oxPAPC.
Effect of increasing amounts of serum derived from non-
smokers and smokers, of LPDS derived from smokers and
of increasing concentrations of oxPAPC on NO
production in HUVECs
NO production was monitored by following levels of nitrite in
the supernatants of HUVECs by a fluorimetric assay as previously
described [31,34].
Basal NO production in culture was measured by incubating
HUVECs without (control) and with increasing amounts (10–50%)
of serum (total volume 300 mL) derived from non-smokers and
smokers, with LPDS derived from smokers and with increasing
concentrations(25–150 mg/mL)ofoxPAPCin24-welltissueculture
plates. After 12 hours, basal NO production in the supernatant was
determined. To measure stimulated NO production in culture, the
supernatants were removed after 12 hours, the cells were washed
and fresh medium was added to each well followed by stimulation
with bradykinin (100 nmol/L), for 10 min at 37uC in the presence
of 5 mmol/L arginine and 3 mmol/L tetrahydrobiopterin.
Effectofserumderived from non-smokers, ofLPDS derived
from smokers,and of increasing amountsof serum derived
from smokers and of increasing concentrations oxPAPC on
Nrf2/ARE pathway expression in HUVECs
HUVECs were incubated for 12 hours at 37uC with 50% of
serum derived from non-smokers, 50% of LPDS derived from
smokers and with increasing amounts (10–50%) of serum derived
from smokers. HUVECs were also incubated for 6 hours in M-199
containing 0.2% FCS with increasing concentrations (25–150 mg/
mL) of oxPAPC.
Real time RT-PCR quantification of RNA Nrf2, GCLC and
HO-1 expression
QuantitativeReal-TimePCR. Total RNAwasextracted,and
real-time RT-PCR was conducted as previously described [21,26].
In brief, RNA was extracted from HUVECs with an RNeasy Mini
Kit (Qiagen) and was reverse transcribed using an IScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). The relative expression
levels of mRNA encoding Nrf2, GCLC, HO-1 and b-actin were
measured by iCycler (Bio-Rad, Hercules, CA), using IQSYBR
Green PCR SuperMix (Bio-Rad, Hercules, CA) and 300 nM of
each primer pair. Primers were designed by Beacon Design 4.0
software (PREMIER Biosoft International, Palo Alto, CA, USA)
and synthesised by MWG Biotech AG (Ebersberg, Germany): Nrf2,
sense 59-TTCAGCCAGCCCAGCACATC-39 and antisense 59-
CGTAGCCGAAGAAACCTCATTGTC-39; GCLC, sense 59
CGAATTCGCCAAGAATGAGGAGATCC-39, antisense 59-C -
GAATTCGAAAGCGACGGCTGTACC-39; HO-1, sense 59-G-
GTGACCCGAGACGGCTTC-39 and antisense 59-AGACTG-
GGC TCTCCTTGTTGC- 39; b-actin, sense 59- ATCAAGAT-
CATTGCTCCTCCTG-3 and antisense 59- GCAACTAAG-
TCATAGTCCGCC-39. Expression levels were normalised to the
level of b-actin.
Western blotting analysis
Western blot analysis for GCLC and HO-1 protein expression
in HUVECs was performed as previously described [21,26].
Nuclear extract for Nrf2 was obtained by utilizing a nuclear
extract kit from Active Motif (Rixensart, Belgium).
siRNA-mediated knockdown of Nrf2
HUVECs were transfected with siRNA against Nrf2 siRNA (59
GUUUUUCCAGCUCAUACUCUUTT-39), or negative control
Nrf2, GSH in Smokers with Endothelial Dysfunction
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treated with 75 mg/mL oxPAPC for 6 hours for the measurement
of the expression levels of GCLC and HO-1.
Statistical analysis
Data are expressed as mean6SD values if normally distributed.
Differences between two groups were analysed by a two-tailed
unpaired Student’s t-test. Statistical comparison among three
groups was performed by one-way ANOVA. The relationship
between variables was assessed by linear regression. A probability
value (P) of 0.05 was considered to be statistically significant. All
data were analysed with StatView (SaS).
Results
No significant differences existed between the two groups of non-
smokers and smokers with respect to age (27.264.4 versus 29.365.6
years, respectively), gender (male/female: 14/12 versus 12/14,
respectively), waist circumference (74.2611.8 versus 73.2610.4 cm,
respectively), body mass index (22.962.7 versus 21.463.0, respec-
tively), systolic (114.268.9 versus 117.669.8 mmHg, respectively)
and diastolic (71.368.3 versus 73.967.5 mmHg, respectively) blood
pressure, heart rate (69.168.8 versus 73.568.1 beat/min, respec-
tively), total cholesterol (179.7633 versus 188.4629.3 mg/dl,
respectively), LDL cholesterol (109.5626.1 versus 124.3619.7 mg/
dl, respectively), HDL cholesterol (44.5610.2 versus 46.4611.9 mg/
dl, respectively), total cholesterol/HDL (4.0760.3 versus 4.0460.5)
and plasma glucose (73.468.9 versus 74.268.5 mg/dl, respectively).
In contrast, smokers had significantly higher concentrations of
oxPAPC both in serum (POVPC 1.0260.31 mmol/L, PGPC
2.8060.39 mmol/L and PEIPC 3.7460.52 mmol/L, P,0.01) and
in PBMC (POVPC 2.260.23 ng/mg PAPC, PGPC 7.1460.91 ng/
mg PAPC, PEIPC 4.8560.47 ng/mg PAPC, P,0.01) compared to
non-smokers (serum: POVPC 0.3260.14 mmol/L, PGPC
1.0660.29 mmol/L, PEIPC 0.9560.22 mmol/L; PBMC: POVPC
0.6160.09 ng/mg PAPC, PGPC 2.1360.57 ng/mg PAPC, and
PEIPC 1.9160.51 ng/mg PAPC, P,0.01). Furthermore, the
concentrations of GSH were significantly lower in smokers
than in non-smokers both in serum (2.660.43 mmol/L versus
5.760.78 mmol/L, respectively, P,0.01) and in PBMC (1.426
0.23 ng/mg cell protein versus 2.9360.32 ng/mg cell protein,
respectively, P,0.01).
Endothelial function
FMD was significantly impaired in smokers compared to non-
smokers (3.261.6 versus 7.962.8%, respectively, P,0.001); on
the contrary, GTN-induced dilation (12.364.1 versus 13.563.8%,
respectively) was similar in both groups, indicating that our
subjects were apparently free of smooth muscle cell disorders.
These data are shown in Figure 1a. Moreover, BA diameters
(3.5260.4 versus 3.8360.5 mm, respectively) were not different
between non-smokers and smokers. Interestingly, we found a
significant positive correlation between the concentrations of GSH
in PBMC and FMD in all subjects (r=0.716, P,0.001), as shown
in Figure 1b.
Effect of serum derived from non-smokers and smokers
and of LPDS derived from smokers on intracellular GSH,
ROS and NO concentration, and on Nrf2/ARE pathway
(mRNA and protein) expression in HUVECs
Incubation of HUVECswith increasing amounts of serum derived
from smokers for 12 hours resulted in a dose-dependent significant
decrease (P,0.01, at 30 and 50%) of GSH concentrations compared
to serum derived from non-smokers (Figure 2a). Moreover serum
derived from smokers induced a dose-dependent increase (P,0.01 at
30 and 50%) of intracellular ROS formation (Figure 2b), whereas
serum from non-smokers did not. The cumulative production of NO
as evaluated by measuring levels of nitrite in the supernatant of cell
culture was significantly increased after stimulation of HUVECs with
bradykinin (Figure2c).The levelsof nitrite inthe supernatant of basal
and bradykinin-stimulated endothelial cells dose-dependently
dropped (P,0.01 at 30 and 50%) after preincubation of HUVECs
with serum derived from smokers; on the contrary, serum derived
from non-smokers did not reduce nitrite concentration in the
supernatants of HUVECs (Figure 2c).
Since the majority of circulating oxPAPC is carried by
lipoproteins [6], we used LPDS to eliminate its effect from
smokers’ serum. The incubation of HUVECs with smokers’ LPDS
almost completely abolished the increase in ROS and the decrease
in GSH and in nitrite induced by smokers’ serum (Figure 2 a–c).
To determine whether intracellular GSH depletion may be due
to its reduced synthesis and based on these results, we then
evaluated the effect of increasing amounts (10–50%) of serum
derived from smokers, of serum derived from non-smokers and of
LPDS (50%) on Nrf2 and GCLC expression. Our results show
that both Nrf2 (Figure 3a) and GCLC (Figure 3b) mRNA and
protein expression (Figure 3d) was dose-dependently decreased
(P,0.01 at 30 and 50%) in HUVECs incubated with serum
derived from smokers, compared to HUVECs incubated with
serum of non-smokers and with LPDS derived from smokers. To
further examine the consequences of nuclear levels of Nrf2 we also
examined the expression of another Nrf2-regulated antioxidant
gene, HO-1. As shown in Figure 3, serum derived from smokers
also dose-dependently reduced (P,0.01 at 30 and 50%) both
mRNA (c) and protein expression (d) of HO-1, compared to serum
derived from non-smokers and with LPDS derived from smokers.
Effect of increasing concentrations of oxPAPC on
intracellular ROS, NO and GSH concentrations, and on
Nrf2, GCLC and HO-1 (mRNA and protein) expression in
HUVECs
To test the hypothesis that the increased oxidative stress in
smokers may have a causal role in the repression of Nrf2/ARE
pathway which in turn may reduce GSH concentration, we
exposed HUVECs to increasing concentrations of oxPAPC (from
25 to 150 mg/mL) for 6 hours. Figure 4a shows a progressive slight
increase of intracellular GSH concentration at the lowest
concentrations (from 25 to 75 mg/mL), whereas at the highest
concentration, GSH was significantly decreased (P,0.01). The
incubation of HUVECs with increasing concentrations of oxPAPC
induced a dose-dependent increase (P,0.01 at the highest
concentration) in intracellular ROS formation (Figure 4b); on
the contrary, a dose-dependent decrease (P,0.01 at the highest
concentration) in basal and bradykinin-induced intracellular NO
concentration was observed (Figure 4c).
Our results also show that Nrf2, GCLC and HO-1 (mRNA and
protein) expression was dose-dependently increased in HUVECs
incubated with the lowest concentrations of oxPAPC (from 25 to
75 mg/mL, P,0.01), while Nrf2, GCLC and HO-1 (mRNA and
protein) expression was repressed in HUVECs incubated with the
highest concentration of oxPAPC, as shown in Figure 5 (a–d).
Nrf2 is required for oxPAPC-stimulated GCLC and HO-1
expression
To determine whether Nrf2 is required for oxPAPC-stimulated
GCLC and HO-1 expression, we used siRNA to knockdown the
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expression (data not shown). Figure 6 (a and b) shows that the
knockdown of Nrf2 was associated to a significant reduction
(P,0.01) of GCLC and HO-1 (mRNA and protein) expression
induced by oxPAPC in HUVECs.
Discussion
The core findings of our study performed in young, otherwise
healthy subjects are the following: 1) FMD, which was significantly
impaired in the smoking group, positively correlated with the
concentrations of GSH in PBMC of all subjects; 2) PBMC
obtained from young smokers, used as in vivo surrogates of
endothelial cells, showed lower concentrations of GSH and higher
concentrations of oxPAPC than non-smokers. We explored the
possible mechanism by which endothelial GSH depletion affects
endothelial function and found that in HUVECs exposed to the
highest amount of smokers’ serum or when cells where incubated
with the highest concentration of oxPAPC: a) GSH concentrations
were significantly reduced, b) ROS formation was significantly
increased, whereas NO concentration was significantly decreased,
c) the expression of the protective Nrf2 and of downstream genes
was significantly reduced. Although the effects of smokers’ serum
on HUVECs may be dependent from different factors than
Figure 1. Endothelial function and correlation between flow-mediated vasodilation (FMD) and concentrations of GSH in peripheral
blood mononuclear cells (PBMC) of non-smokers and smokers. FMD and glyceryl trinitrate (GTN)-induced vasodilation in non-smokers and
smokers (A); correlation between FMD and intracellular concentrations of GSH in PBMC of non-smokers and smokers (B). Data are presented as
mean6SD; FMD and GTN are expressed as maximal percentage change in brachial artery dilation. *P,0.001 versus non-smokers.
doi:10.1371/journal.pone.0030291.g001
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30291Figure 2. Effect of serum derived from non-smokers and smokers and of lipoprotein-depleted serum (LPDS) derived from smokers
on intracellular GSH concentration, on intracellular reactive oxygen species (ROS) and on nitric oxide (NO) formation in human
umbilical vein endothelial cells (HUVECs). Confluent HUVECs were incubated without and with 10, 30 and 50% serum derived from non-
smokers and smokers and with the corresponding LPDS derived from smokers for 12 hours. Figure shows intracellular GSH concentration (A),
intracellular ROS (B) and cumulative basal and bradykinin-stimulated NO production, evaluated by measuring levels of nitrite in the supernatants (C).
Data are presented as mean6SD of measurements performed in triplicate in four different occasions; *P,0.01 versus control (no addition of serum
derived from the subjects) non-smokers’ serum and smokers’ LPDS.
doi:10.1371/journal.pone.0030291.g002
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did not repress Nrf2/ARE pathway expression strongly suggests
that oxPAPC may play a key role in smokers’ serum-dependent
effects in HUVECs.
Taken together our results suggest that, in young heavy smokers
with endothelial dysfunction, oxidative stress induced by cigarette
smoking results in a repression of the Nrf2/ARE pathway leading
to intracellular GSH deficiency.
Although several evidence indicate that cigarette smoking
induces systemic oxidative stress in humans (reviewed in [2]),
data from in vitro [36] and clinical studies [37] have shown that
smoking is also associated with a decline in the endogenous GSH-
dependent detoxification systems [1,2]. In the present study, the
evidence of increased concentrations of oxPAPC, a reliable marker
of oxidative stress [5], and of decreased concentrations of GSH in
serum and in PBMC of young heavy smokers is in line with our
previous data showing a progressive increase of oxidative stress in
PBMC of young smokers (from moderate to heavy), which was
coupled with a progressive decrease of GSH [21].
FMD of the brachial artery is currently the most frequently used
non-invasive surrogate of endothelial function [22,23], and it has
been convincingly demonstrated to reflect endothelium-dependent
vasodilation mediated by NO [38]. In this study we found that
FMD was impaired in young heavy smokers, whereas GTN-
induced vasodilation was not affected. Our results are consistent
with previous observations showing a loss of FMD in young
smokers [15–17], without affecting smooth muscle cell function
[17].
Although it has been suggested that cigarette smoking produces
endothelial dysfunction mainly by reducing NO bioavailability
[15,18,19], the precise mechanism is complex and remains under
investigation. The majority of in vitro data has involved the use of
CS extract (CSE); however, this solution is probably not
physiological, because in the circulation, certain toxic components
may be neutralized by the antioxidants present in the blood (15).
Therefore to simulate a physiological environment, serum from
the subjects was used as a vehicle of CS exposure in our in vitro
model. In the present report we provide evidence that smokers’
serum increased ROS formation and reduced NO production in
HUVECs, compared to serum from the non-smokers’ group.
Under similar experimental conditions, these results are consistent
with earlier demonstrations that endothelial cells exposed to
smokers’ serum decreased NO production and endothelial NO
synthase activity [15,39].
To clarify if this reduced NO production was due to the higher
concentrations of oxPAPC found in smokers’ serum, and based on
Figure 3. Effect of serum derived from non-smokers and smokers and of lipoprotein-depleted serum (LPDS) derived from smokers
on Nrf2, GCLC and HO-1 expression in human umbilical vein endothelial cells (HUVECs). Confluent HUVECs were incubated without and
with increasing amounts (10, 30 and 50%) of serum derived from smokers (serum S 10, serum S 30, serum S 50), with 50% serum derived from non-
smokers (serum N–S 50) and with 50% LPDS derived from smokers (LPDS S 50) for 12 hours. mRNA for Nrf2, GCLC and HO-1 (A–C) was analysed by
quantitative Real-Time PCR. Normalised gene expression levels were given as the ratio between the mean value for the target gene and that for beta-
actin in each sample. Results are reported as the mean6SD of measurements performed in triplicate. *P,0.01 versus non-smokers and LPDS. (D)
shows a representative Western blot analysis of three independent experiments for nuclear Nrf2, for GCLC and HO-1.
doi:10.1371/journal.pone.0030291.g003
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30291Figure 4. Effect of increasing concentrations of oxPAPC on intracellular GSH concentration, on intracellular reactive oxygen species
(ROS), and on nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). Confluent HUVECs were incubated
without and with increasing concentrations (25–150 mg/mL) of oxPAPC for 6 hours. Figure shows intracellular GSH concentration (A), intracellular ROS
(B) and cumulative basal and bradykinin-stimulated NO production, evaluated by measuring levels of nitrite in the supernatants (C). Data are presented
as mean6SD of measurements performed in triplicate in four different occasions. *P,0.01 versus oxPAPC 0 e 75 mg/mL. # P,0.01 versus basal NO.
doi:10.1371/journal.pone.0030291.g004
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generation of ROS in PBMC [21], we exposed HUVECs to
increasing concentrations of oxPAPC. Our data demonstrated a
dose-dependent increase in ROS formation that was paralleled to
a dose-dependent basal and bradykinin-stimulated NO decrease in
HUVECs. Taken together, these findings indicate that the
increased oxidative stress shown in young smokers plays a causal
role in the reduced endothelial NO production.
However, our results uniquely demonstrate that FMD was
closely associated with the concentrations of GSH in PBMC in all
subjects. Although recent data suggest a relationship between
decreased plasma GSH concentrations and impairment of
postprandial endothelial function in menopausal women [40]
and a positive relationship between FMD and plasma GSH in
smokers [20], to our knowledge this is the first report that indicates
that cellular GSH concentrations correlate with FMD in young
subjects. These data, together with the demonstration of decreased
levels of GSH in plasma and in PBMC of smokers, led us to
speculate that a further important consequence of the increased
oxidative stress found in young smokers may be an endothelial
GSH depletion. The results from our in vitro study confirmed this
hypothesis; in fact, smokers’ serum compared to non-smokers’
serum reduced intracellular GSH concentrations in HUVECs and
decreased the expression of Nrf2, of HO-1 and of GCLC, which is
the catalytic subunit of the rate-limiting enzyme for the GSH de
novo synthesis [9]. These results are of particular relevance because
it is well known that GSH plays a major role in antioxidant cell
protection [9], and that the Nrf2/ARE pathway is crucial for the
regulation of intracellular redox state [10].
Recent studies have shown a decline of Nrf2 expression in
pulmonary macrophages of current smokers [41] and an increased
susceptibility to CS-induced emphysema in Nrf2-deficient mice
[42] suggesting a protective role of Nrf2 in CS-lung injury [43].
Moreover we have recently shown that the protective Nrf2/ARE
pathway in PBMC was overexpressed only in moderate smokers,
whereas it was repressed in heavy smokers [21] indicating that
heavy smokers, contrary to moderate smokers, do not appropri-
ately react to the intracellular oxidative stress in terms of Nrf2/
ARE activation. Interestingly, in the present study this inadequacy
of response was observed not only in vivo but also in vitro, where we
showed that low concentrations of oxPAPC slightly increased
GSH and Nrf2/ARE gene expression, whereas oxPAPC at
concentration similar to that found in the smokers’ serum
significantly reduced GSH concentrations and did not cause the
activation of the Nrf2/ARE pathway. Our data are in line with
recent studies (reviewed in [6]) demonstrating that oxPAPC
induces both a complexity of pro-inflammatory and pro-
atherosclerotic effects (including increase in intracellular ROS
levels and GSH depletion in endothelial cells), as well as tissue-
protective and anti-inflammatory activities through induction of
phase II genes mediating protection from oxidant stress. In this
context it has been recently shown that low concentrations of
Figure 5. Effect of increasing concentrations of oxPAPC on Nrf2, GCLC and HO-1 expression in human umbilical vein endothelial
cells. mRNA (A–C) was analysed by quantitative Real-Time PCR. Normalised gene expression levels were given as the ratio between the mean value
for the target gene and that for beta-actin in each sample. Results are presented as the mean6SD of measurements performed in triplicate.*P,0.01
versus oxPAPC 0 and 150 mg/mL. Figure (D) shows a representative Western blot analysis of three independent experiments for nuclear Nrf2, GCLC
and HO-1.
doi:10.1371/journal.pone.0030291.g005
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antioxidant enzymes such as GCLM and HO-1, through
activation of Nrf2 [44].
In these conditions, of course, the reduction of GSH may also
be the result of a net loss of GSH, since cigarette smoke-dependent
ROS have already been shown to cause a fall of reduced GSH not
accompanied by an increase of oxidized GSH [45].
Moreover the induction of GCLC and HO-1 appeared to be
critically dependent on Nrf2, because suppression of Nrf2
expression by siRNA was associated to a significant reduction of
HO-1 and GCLC expression induced by oxPAPC in HUVECs.
These data agree with a recent in vitro study showing that long term
CS exposure led to decreased HO-1 expression concomitantly
with nuclear Nrf2 decrease in human macrophage cell line [46].
Furthermore, since recent evidence suggests that HO-1 can
improve vascular function by enhancing NO bioavailability [47],
the serum oxidative stress-induced repression of HO-1 showed in
this study may, at least in part, have contributed to the decreased
endothelial NO production.
There is also evidence suggesting a complex and interesting
interaction between NO and GSH [48] and in particular a recent
study showed that NO increased the synthesis of GSH in
Figure 6. Effect of small interfering (si) and scrambler (sc) RNA against Nrf2 on oxPAPC-dependent expression of GCLC and HO-1 in
human umbilical vein endothelial cells. mRNA (a) was analyzed by quantitative Real-Time PCR. Normalized gene expression levels were given as
the ratio between the mean value for the target gene and that for the beta-actin in each sample. Figure shows a representative Western blot analysis
for GCLC and HO-1 and the average quantification obtained by densitometric analysis of all the samples (b). Data on Western blot analysis are
expressed as the density ratio of target to control (beta-actin) in arbitrary units 610. Results are the mean6SD of measurements performed in
triplicate in four different occasions. *P,0.01 versus control; {P,0.01 versus scRNA; #P,0.01 versus oxPAPC+scRNA.
doi:10.1371/journal.pone.0030291.g006
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the activation of Nrf2 [49]. We can therefore speculate that the
endothelial NO decrease induced by serum from smokers found in
this study may have an additional effect on oxidative stress-
induced repression of Nrf2/ARE pathway.
In conclusion, the results of this study support the notion that in
young healthy smokers with endothelial dysfunction, a novel
further consequence of increased oxidative stress is an endothelial
decrease of Nrf2 and GCLC expression with consequent GSH
depletion.
Although our in vitro results and the correlation between
intracellular GSH and FMD suggest that intracellular GSH
depletion may have a role in endothelial dysfunction of young
smokers, we cannot draw a definite conclusion and further studies
are needed.
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